Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jul 15, 2022; 14(7): 1252-1264
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1252
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1252
Table 1 Classification of sample types investigated by claudin 18.2 staining
| Sample type | Samples, n | CLDN18.2 expression | |
| Positive fraction ≥ 1%, n (%) | Staining intensity = 3+, n (%) | ||
| PDAC | 93 | 88 (94.6) | 50 (56.8) |
| Para-cancerous | 86 | 81 (94.2) | 32 (39.5) |
| Normal | 13 | 0 (0.0) | 0 (0.0) |
- Citation: Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264
- URL: https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i7.1252